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Background: Resistance development to antimalarial drugs necessitates the look at traditional medicinal plants as 
sources of novel compounds that could have the otential to be developed into new antimalarial therapies. Four 
medicinal plants used in Kenya to treat malaria were investigated. 
Objective: To determine the in vitro and in vivo antimalarial activity and safety of four medicinal plants used in Kenya 
to treat malaria. 
Materials and Methods: Ximenia americana, Sericocomopsis hilderbrandtii, Pentas lanceolata and Fuerstia africana 
were collected from their habitat, dried, and extracted with methanol and aqueous solvents. In vitro antiplasmodial 
activity carried out using Plasmodium falciparum, In vivo antimalarial activity using Plasmodium berghei ANKA strain 
in Swiss albino mice. Cytotoxicity was carried out using MTT assay on VeroE99 cell lines, acute toxicity was 
investigated in Swiss albino mice.  
Results: All extracts had good in vitro activity against D6 strain of Plasmodium falciparum with IC50<20µg/ml.  Aerial 
parts of Fuerstia africana methanol extract had the highest in vitro activity.  Seven extracts showed good in vivo 
activity with chemosuppresion >30% while three demonstrated low activity. Fuerstia africana was moderately 
cytotoxic. Except for Ximenia americana water extract, all the extracts were safe with LD50 > 5000mg/Kg.  
Conclusion: Results of this study support medicinal use of these plants and indicate that useful compounds can be 
isolated for further exploitation, formulation and use. 
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1. Introduction 
Malaria is a life threatening vector borne infection, 
caused by the protozoan Plasmodium parasite. Globally, 
an estimated 3.4 billion people are at risk of malaria 
(WHO 2014), with Africa bearing over 90% of the global 
malaria burden (Snow et al, 2005). Malaria accounts for 
30% of outpatient cases and 19% of admissions (WHO 
2008; Kigondu et al, 2011).  
  
Symptoms of malaria include fever, headache, loss of 
appetite, diarrhea, joint pains and chills. Severe malaria 
presents frequently as severe anemia and or cerebral 
malaria. Malaria is also responsible for complications in 
course of pregnancy (Malaney, et al, 2004). And can lead 
to chronic debilitation with delays in cognitive and 
physical development (Breman, et al, 2004) all of which 
have a negative impact on the social and economic 
development of affected countries (Sachs, et al, 2002).  
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Currently artemisinine combination treatments are the 
recommended first line therapy for falciparum malaria 
(Gathirwa et al, 2011). However P. falciparum parasites 
with reduced in vivo susceptibility to artemisinine 
derivatives have emerged in western Cambodia (Noedl, 
2008, Dondorp, 2009). Using artemisinine or its 
derivatives as monotherapy leads to resistance 
development (Dondorp, et al, 2010; Gathirwa et al, 
2008), while addition of artemisinine with a drug that 
has failed locally leads to a failed combination 
(Mutabingwa, et al, 2005). Furthermore production of 
ACTs to meet global demand is costly as it is limited by 
global shortage of materials (Whitty, et al, 2004; 
Kigondu et al, 2011). The threat of parasite resistance to 
artemisinine and its derivatives (Noedl, 2010), having 
lost other drugs to resistance such as chloroquine 
(Spencer, 1985), quinine (Pickard and Wermsdofer, 
2002), sulphadoxine pyrimidimine (White, et al, 2010), 
and mefloxine (Wongsrichanalai et al, 2001) is 
worrying. There is therefore need for development of 
new antimalarial drugs that are affordable to combat 
increasing parasite resistance. 
Plants have been considered a rich source of new drugs 
(Kiria et al, 2006). Some antimalarial drugs in use today 
such as quinine and artemisinine originated from plants 
(Ravikumar, et al, 2010; Muthaura et al, 2007). Quinine 
for example was extracted from the bark of Cinchona 
plant originally grown in Peru (Greenwood, 1992; 
Rukunga et al, 2009), while artemisinine was extracted 
from a Chinese herb, qinghao or Artemisia annua 
(Klayman, 1985; Muthaura et al, 2007). Medicinal plants 
provide cheap alternative therapeutic agents than 
conventional drugs      (Muregi et al, 2007; Gathirwa et 
al, 2011). Additionally drugs derived from natural 
products tend to have fewer side effects (Breman et al, 
2004). Infact, traditional medicinal plants have been 
used for a long time in malaria endemic regions to treat 
malaria (Gessler et al, 1995; Kokwaro, 1993; Koch, 
2005; Gathathi, 2009) without the exact knowledge on 
efficacy and safety. 
In the effort to determine the efficacy and safety of 
traditionally used medicinal plants, four medicinal 
plants, used to treat malaria in Kenya were targeted. 
These included Sericocomopsis hildebrandtii Schinz, 
Pentas lanceolata (Forssk.) Defleurs, Fuerstia africana 
T.C.E. Friers, and Ximenia americana L. The antimalarial 
and toxicity activities of these four medicinal plants 
were investigated. 
2. Methodology 
2.1 Plant materials 
The plant samples used in this study were collected in 
Kajiado, Embu and Baringo Counties based on 
ethnopharmacological information, and were identified 
by a taxonomist at the East Africa Herbarium, National 
Museums of Kenya, Nairobi where voucher specimens 
were deposited. They were dried indoors and powdered 
using an electric mill. 
2.2 Preparation of the plant materials 
For each plant part, 50 g of powder was extracted by 
soaking in methanol and distilled water, separately. The 
extracts were decanted and filtered through Whatman 
filter paper and re-extracted again for 24 hr. The 
extraction process was repeated until a clear extract 
was obtained. The filtered extracts were combined and 
methanol removed under reduced pressure at 40 °C 
(Harborne, 1998) while aqueous extracts were freeze 
dried with a freeze drier (Edwards freeze dryer 
Modulyo) dry samples were stored in a freezer at −4 °C. 
Table 1 presents the plant species and yields of the 
water and methanol extracts. 
2.3 Parasites 
Chloroquine sensitive P. berghei strain ANKA donated 
by International Livestock Research Institute, ILRI, 
Kenya was used in the in vivo assay. While two strains 
were used for in vitro sensitivity test ; Chloroquine 
sensitive  (D6) strain from Sierra Leone and 
Chloroquine resistant (W2) strain from Indochina, 
donated by the Division of Experimental Therapeutics, 
Walter Reed Army Institute of Research, Washington 
DC. 
2.4 Preparation of test extracts 
Stock solutions of aqueous extracts (10 mg/ml) were 
made in distilled deionized water and filter sterilized 
using 0.22 µm membrane filters in a laminar flow hood. 
Methanol extracts were dissolved in DMSO (Sigma 
Chemical Co., USA) followed by subsequent dilution to 
lower concentration of DMSO, to <1% to avoid carry 
over (solvent) effect (Dorin et al, 2001). Reference 
drugs, CQ diphosphate and Artemisinine at a 
concentration of 1 µg/ml each, were similarly prepared 
and all solutions stored at −20 °C until used. 
2.5 Cultures of Plasmodium falciparum 
P. falciparum culture of D6 and W2 strains were used in 
the study. The culture media was a variation of that 
described by Trager and Jensen (1976) and consisted of 
RPMI 1640 supplemented with 10% serum 
(Schlichtherle et al, 2000). Uninfected human blood 
group O+ erythrocytes (<28 days old) served as host 
cells. The cultures were incubated at 37 °C in an 
atmosphere of 3% CO2, 5% O2, and 92% N2 (BOC, 
Nairobi). 
2.6 In vitro antiplasmodial assay 
The assay protocol that measures the ability of the 
extracts to inhibit the incorporation of [G-3H] 
hypoxanthine (Amersham International, 
Burkinghamshire, UK) into the malaria parasite   
(Desjardins et al, 1979) was used.   Aliquots of culture 
medium (25 µl) were added to all the wells of a 96 well 
flat-bottom microculture plate (Costar Glass Works, 
Cambridge, UK). Aliquots (25 µl) of the test solutions 
were added, in triplicate, to the first wells, and a 
Titertek motorized hand diluter (Flow Laboratories, 
Uxbridge, UK) was used to make two-fold serial 
dilutions of each sample. The sensitivity tests were 
carried out with attainment of ring stage parasite 
growth and initial parasitaemia of 0.4% by applying 200 
µl, 1.5% haematocrit of P. falciparum culture to each 
well. As control, 200 µl of culture media without 
parasites was added into four wells on the last row of 
each plate. Parasitized and non-parasitized erythrocytes 
were incubated at 37 °C in a gas mixture of 3% CO2, 5% 
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O2 and 92% N2. After 48 hr each well was pulsed with 
25 µl of culture medium containing 0.5 µCi of [G-3H] 
hypoxanthine. The plates were incubated for a further 
18 hr. were then harvested onto glass fiber filter mats 
using a 96 well harvester, washed with distilled water 
and dried. [G-3H] hypoxanthine uptake was determined 
using a micro beta trilux liquid scintillation counter 
(Wallac Micro Beta Trilux). Computation of the 
concentration of drug causing 50% inhibition of [G-3H] 
hypoxanthine uptake (IC50) was carried out by 
interpolation after logarithmic transformation of both 
concentration and cpm values using the formula 
described by Sixsmith et al, (1984). 
IC50 =   antilog (logX1 + [(log Y50 − log Y1) (logX2 − logX1)] 
                                     (Log Y2 − log Y1) 
Where Y50 was the cpm value midway between 
parasitisized and non-parasitisized control cultures and 
X1, Y1, X2, and Y2 were the concentrations and cpm 
values for the data points above and below the cpm 
midpoints. 
2.7 In vitro determination of cell cytotoxicity 
Cytotoxic concentration causing 50% cell lysis and 
death (CC50) was determined by a method described by 
Mosmann (1983). Briefly, Vero E99 cells were seeded at 
a concentration of 2.5×104 cells/well in a 24 well plate 
and grown under 5% CO2 at 37 °C in Eagle’s Minimum 
Essential Medium (MEM) supplemented with 5% fetal 
bovine serum (FBS) for 48 hr. The culture media were 
replaced by fresh media containing extract at various 
concentrations, and cells further grown for 24 hr. The 
cells were then treated with trypsin and the number of 
viable cells determined by the tryphan blue exclusion 
method. CC50 was determined from a curve relating 
percent cell viability to the concentration of extract. 
Selectivity index (SI = IC50/CC50) was used as a 
parameter of clinical significance of the test samples by 
comparing general toxins and selective inhibitory effect 
on P. falciparum (Wright and Phillipson, 1990). 
2.8 In vivo antiplasmodial activity 
Swiss albino mice (20±2 g) were used to evaluate 
antimalarial activity using P. berghei strain ANKA, 
maintained by serial passage. The assay protocol was 
based on the 4-day suppressive test described by Peters 
et al, (1975). Briefly, the mice were infected 
interperitonially with 0.2 ml (2×107 parasitized 
erythrocytes). Infected mice were randomly selected 
into groups of five for one test sample and the 
experimental groups treated with a single dose of 500 
mg/kg of the test sample in 0.2 ml orally 2 hr post 
infection (i.e. on day 0)  (Gessler et al, 1995). This was 
repeated after every 24 hr (Day 1, Day 2, and Day 3). 
Two control groups of five mice each were treated with 
a placebo (10% Tween 80) and 5 mg/kg/day of 
Chloroquine for negative and positive controls, 
respectively. Parasitaemia was determined on day 4 (24 
hr after the last treatment) by microscopic examination 
by counting parasites in 4 fields of approximately 100 
erythrocytes per view of thin blood smear sampled 
from the tail of the experimental mouse and stained in 
10% Giemsa solution. The difference between the mean 
number of parasites per view in the negative control 
group (100%) and those of the experimental groups 
was calculated and expressed as percent parasitaemia 
suppression (Tona et al, 2001).  
PS = [(A−B)/A] ×100  
Where, A is the mean parasitaemia in the negative 
control on day 4, and B the corresponding parasitaemia 
in the test group. Standard deviation for the mean 
values was calculated as described by Armitage and 
Berry (1991).  
2.9 Acute toxicity 
Female Swiss albino mice (20±2 g), grouped in to five 
per cage were starved overnight (12 hr) before oral 
administration of a single dose of the extract and 
provided with tap water and food. The extracts were 
dissolved in distilled water and administered by gavage 
at logarithmic dose ranging between 500 and 5000 
mg/kg body weight giving five dose levels of 500, 
889.15, 1581.18, 2811.80 mg/kg body and 5000 mg/kg 
body weight. Behavior observed for 1 hr after the 
treatment, intermittently for 4 hr, thereafter over a 
period of 24 hr (Twaij et al, 1983). Were further 
observed for up to 14 days following treatment for any 
signs of toxicity, and the latency of death. LD50 value 
was determined according to a method described by 
Thompson, (1985).    
3.  Results 
3.1 In vitro antiplasmodial assay  
Methanol extracts exhibited higher antiplasmodial 
activity than water extracts for both strains of P. 
falciparum. All the methanol extracts posted IC50 values 
<5µg/ml, (Tables 2) while aqueous extracts exhibited a 
range of good to moderate activity with IC50 values 
<20µg/ml.  
IC50 value against W2 strain was higher than that of D6 
strain of P. falciparum (Table 3). Methanol extract of F. 
africana (aerial part) showed good activity while the 
others exhibited moderate antiplasmodial activities 
against W2 strain of P. falciparum. Water extracts of of 
F. africana (aerial parts) and P. lanceolata (aerial parts) 
had moderate antiplasmodial activities where as the 
others had low antiplasmodial activities (IC50 >50 
µg/ml) against W2 strain of P. falciparum. 
3.2 In vivo assay. 
For extracts subjected to in vivo assay, 7 had 
chemosuppression >30% while three were in active 
(Table 4). Methanol extract of P. lanceolata and water 
extract of X. americana were the most active and had 
the highest mean survival time. All the water extracts 
were active against P. berghei in mice. Only methanol 
extracts of P. lanceolata and X. americana were active in 
vivo. 
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Table 1: Plant species and yield of water and methanol extracts 
Botanical name Family Part used 
Dry weight of extract    % 
Water extract Methanol Extract 
F.  africana T.C.E. Friers Lamiaceae Aerial part 9.4 3.73 
S.  hilderbrandtii Schinz Amaranthacea Aerial part 7.04 2.08 
  Roots 10.58 2.32 
P. lanceolata (Forssk.) Defleurs Rubiaceae Aerial part 7.06 2.53 
X.  americana L Olacaceae Stem bark 16.38 11.62 
 
Table 2: In vitro antiplasmodial activity (IC50) of extracts of selected medicinal plants against D6 strain of P. 
falciparum 
Plant   Part Used 
Aqueous extract 
IC50 ± SD (µg/mL) 
Methanol extract 
IC50 ± SD (µg/mL) 
S. hilderbrandtii AP 18.004 ±3.62 3.153 ±1.24 
 
R 4.096   ±1.69 2.12   ±0.56 
F. africana AP 17.035 ±4.31 1.841 ±0.82 
P. lanceolata AP 7.127   ±1.73 3.744 ±0.42 
X. americana SB 9.621   ±2.45 2.108 ±0.27 
Chloroquine - 7.649   ±1.82 
 
Artemisinin - 0.962   ±0.33 
 
The IC50 values are expressed as mean ± S.D. of three different determinations per experiment; 
Key: AP = aerial part, R = root SB = stem bark 
 
Table 3: In vitro antiplasmodial activity (IC50) of extracts of selected medicinal plants against W2 strain of P.  
falciparum 
Plant   Part used 
Aqueous extract 
IC50 ± SD (µg/ml) 
Methanol extract 
IC50 ± SD (µg/ml) 
S. hilderbrandtii AP 78.695 ±0.70 12.688 ±4.69 
 
R 54.166 ±4.71 14.851 ±3.37 
F. africana AP 37.981 ±2.43 6.227   ±0.12 
P. lanceolata AP 43.151 ±6.32 14.903 ±2.14 
X. americana SB 83.489 ±7.21 36.791 ±4.51 
Chloroquine - 56.117  ±0.22 
 
Artemisinin - 3.56      ±0.17 
 
The IC50 values are expressed as mean ± S.D. of three different determinations per experiment; 
Key: AP = aerial part, R = root SB = stem bark 
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3.3 Cytotoxicity Assay 
Table 5 summarizes cytotoxicity (CC50) against the 
mammalian Vero E cells of the plant extracts. Methanol 
extracts of F. africana were moderately cytotoxic with 
CC50 of 63.45 µg/ml. The rest of the extracts were not 
cytotoxic at 100 µg/ml. 
3.4 Acute toxicity 
Stem bark of X. americana, aqueous extract 
demonstrated 2 deaths within 40 min. The mice treated 
with the rest of plant extracts continued to gain weight 
at a similar rate to that seen in the untreated controls 
with no external toxic effects observed within 14 days.  
X. americana methanol extract was not tested since it 
could not dissolve at 5000 mg/kg. 
 
Table 4: In vivo anti-malarial activity of selected medicinal plant extracts on Plasmodium berghei in mice 
Extract/Drug Part Used Solvent Route 
Dose 
(Mg/kg/Day) 
Parasite 
Density 
% chemo- 
Suppression 
Mean 
survival time 
F.  africana  AP MeOH Oral 500 25.14 ± 3.65 27.88 ± 3.47 10.6 ±1.51 
F. africana AP H2O Oral 500 20.79 ± 2.02 30.80 ± 2.80 10 ± 2.94 
S. hilderbrandtii AP MeOH Oral 500 28.74 ± 0.72 17.53 ± 2.07 10 ± 2.91 
S. hilderbrandtii  AP H2O Oral 500 23.04 ± 1.88 33.89 ± 3.41 8.8 ± 1.30 
P. lanceolata  AP MeOH Oral 500 12.23 ± 0.04 64.92 ± 0.14 11.4 ±3.28 
P. lanceolata AP H2O Oral 500 20.55 ± 1.42 41.04 ± 2.02 10 ± 2.91 
X. americana SB MeOH Oral 500 17.15 ± 3.58 50.81 ± 0.28 11.6 ±3.28 
X. americana SB H2O Oral 500 15.73 ±0.036 54.87 ± 0.38 9.3 ± 1.25 
S. hilderbrandtii R MeOH Oral 500 30.45 ± 2.18 12.63 ± 1.26 9.8 ± 1.64 
S. hilderbrandtii R H2O Oral 500 24.30 ± 4.29 30.29 ± 2.31 9.2 ± 1.30 
Positive control 
Chloroquine 
- - Oral 10 1.11 ± 0.46 96.80 ± 1.37 15 ± 1.34 
Negative control 
Tween 80 
- - Oral 0.2 ml/day 34.85 ± 2.87 - 8.8 ± 1.28 
Results are expressed as means ± SD of 5 determinations per experiment  
Table 5: Cytotoxicity (CC50) of plant extracts to Vero E cells. 
Plant  Plant part used Extract CC50 µg/ml IC50 µg/ml 
Selectivity 
index (SI) 
F. africana  
 
AP 
 
Methanol 
Water 
63.45 
≥100 
1.841 
17.035 
34.465 
NC 
S.  hilderbrandtii 
 
AP 
 
Methanol 
Water 
≥100 
≥100 
3.15 
18.004 
NC 
NC 
P. lanceolata  
 
AP 
 
Methanol 
Water 
≥100 
≥100 
3.744 
7.127 
NC 
NC 
X. americana 
 
SB 
 
Methanol 
Water 
≥100 
≥100 
2.108 
9.621 
NC 
NC 
S. hilderbrandtii R 
 
Methanol 
Water 
≥100 
≥100 
3.948 
4.046 
NC 
NC 
SI: selectivity index, is defined as the ratio of the CC50 value determined on the mammalian cell line on the IC50 value 
determined on P. falciparum (D6) 
NC: Not cytotoxic at the highest concentration tested 
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4. Discussion 
Yields of water extracts were higher than those of 
methanol extracts. Water being more polar than 
methanol is able to extract more compounds, evident in 
other studies (Muthaura et al, 2007 ; Kigondu et al, 
2011). W2 being a resistant P. falciparum strain, 
exhibited lower activity than D6. Methanol extracts had, 
higher activity against both strains of P. falciparum than 
water extracts. This could be due to active constituents 
responsible for activity which extracts more in 
methanol as already observed by Kirira et al (2006) 
Generally the plants tested were not as active as the 
reference drug artemisinine (IC50 0.962 µg/ml for D6 
strain and 3.56 µg/ml for W2 strain of P. falciparum). 
Since the extracts were heterogeneous mixture of 
different compounds. Isolating pure compounds from 
the extracts may give similar IC50 values as 
artemisinine, considering that plant extracts with  IC50 
values often <10 µg/ml (Nkunya et al, 1991) are 
potential source of antimalarial compounds. For 
instance Artemisia annua (IC50, 3.9 µg/ml) (Phillipson 
and Wright 1991) resulted in lead antimalarial 
compound  artemisinine. The fact that all methanol 
extracts were more active than CQ confirms and 
validates the medicinal plants as already used in 
traditional setting. 
Methanol extract of F. africana (aerial parts) recorded 
the highest activity in vitro against both strains of P. 
falciparum. This is in agreement with a previous study 
where the dichloromethane extract of the leaves of  F. 
africana were reported to exhibit high in vitro 
antiplasmodial activity (IC50 3.8 μg/ml, Kigondu et al, 
2011). Aerial parts consist of leaves and flowers. 
Flowers may contain more active compounds against P. 
falciparum than the leaves alone as used in literature. 
Methanol is a more polar solvent than dichloromethane, 
consequently, it may have resulted in extraction of more 
antimalarial compounds, hence the higher activity in 
this study. However the methanol extracts of F. africana 
(aerial parts) were inactive in vivo. This differs with 
literature where earlier investigations by Muthaura, 
(2007), revealed F. africana to have a 
chemosuppression of 61.85±4.61% and 43.16±1.69% 
for methanol and water extracts respectively. This 
disparities could be due to difference in seasons of 
harvesting, geo-reference, plant-part used intra-species 
variations and plant age that affect the presence and 
quantities of bioactive compounds in plants (Weenen et 
al, 1990). 
Notably apart from methanol extracts of F. africana 
(aerial parts), S. hilderbrandtii (aerial parts and roots) 
also exhibited inactivity in the mouse model despite 
high in vitro activity.  As described by Gassler et al, 
(1995), in vitro activity may not necessarily translate to 
in vivo activity. This can be attributed to poor 
bioavailability, low absorption, poor transport 
(Muthaura, 2007) and or alteration of structures that 
enhance activity by metabolic processes in mice 
(Muregi, 2007). 
However, the water extracts of F. africana (aerial part) 
and S. hilderbrandtii (roots and aerial parts) showed in 
vivo antimalarial activity, despite moderate in vitro 
activity against D6 strain of P. falciparum. It is likely that 
some of the compounds in the extracts are converted to 
active metabolites  resulting in bioactivity in vivo 
(Muregi et al, 2007). In addition, the results presented 
here are supported by Gachathi, 1989 and Kokwaro, 
1993 who have documented the ethnomedicinal use of 
water extracts of S. hilderbrandtii  and F. africana  and 
others in traditional medicine. 
The methanol extract of the aerial parts of P. lanceolata, 
had high activity in vitro, (IC50 3.744± 0.42 µg/ml) 
previous investigation has shown petroleum ether root 
extract of P. lanceolata to have an IC50 of 58.5±4.7, and 
33.91±1.06 µg/ml against D6 strain,and W2 strain of P. 
falciparum respectively (Kigondu, 2011). This 
difference can be attributed to the solvents and the 
plant parts used. Methanol appears to be a better 
solvent for extraction of active antimalarial compounds 
than petroleum ether, hence the observed higher 
activity in this study. Secondly aerial parts (leaves and 
flowers) used in this study possess a higher number of 
antiplasmodial compounds. This is mainly because the 
aerial parts manufacture more secondary metabolites 
than the roots. This finding is encouraging as this 
prevents the plant from over exploitation since aerial 
parts can be harvested leaving behind the rest of the 
plant to continue growing hence environmental 
conservation.  
Aerial parts of P. lanceolata consistently exhibited good 
in vivo and in vitro activity, lack of cytotoxicity on Vero E 
cells and the lack of toxicity in mice, confirming that P. 
lanceolata is an effective and safe antimalarial herb. 
This validates its use as an antimalarial as used in 
traditional medicine. The knowledge that the methanol 
extract is more active in vivo than water extract is useful 
since water is mainly used in preparation of herbal 
remedies.  
The methanol extracts of the roots and aerial parts of S. 
hilderbrandtii had high in vitro activity in this study. 
This agrees with literature where the roots of S. 
hilderbrandtii (CHCl3 extract) have been reported to 
have IC50 of 3.8 µg/ml against D6 strain of P. falciparum 
(Koch et al, 2005). This affirms more the potential of 
this plant as a future antimalarial. 
The roots of S. hilderbrandtii (methanol extracts) had 
higher antiplasmodial activity than the aerial parts. This 
trend was similar for water extracts, where the roots 
had higher antiplasmodial activity than the aerial parts. 
This could be due to the fact that roots act as storage 
organs in most plants (Babitha et al, 2002) and hence 
store phytochemical compounds in high concentration 
manufactured in the leaves and transported to the roots 
for storage. This is encouraging since extract yields 
from the roots were found to be higher than from the 
aerial parts hence more availability for use.  
Both methanol and water extracts of X. americana had 
good in vitro and in vivo activity against D6 strain of P. 
falciparum and P. berghei respectively. Notably the 
water extract had higher activity than the methanol 
extract in vivo. This is probably due to 
biotransformation of constituents into more active 
metabolites in mice (Muregi, et al, 2007). This 
knowledge is encouraging since water is mainly the 
formulation used in the traditional preparation of 
herbal remedies (Kokwaro 1993, Gachathi, 1989; 
Bentjee, 1994). Although not much has been reported 
about antimalarial activity of X. americana, its 
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traditional use as an antimalarial has been reported by 
Gronhaug et al, (2008) and Diallo et al, (2002). 
Therefore this study confirms the high potential of this 
plant as a future antimalarial. And partially validates its 
use as an antimalarial as used in the traditional 
medicine. 
Stem bark of X. americana and aerial parts of P. 
lanceolata methanol extracts had the highest 
chemosuppression with higher mean survival time 
(11.60 and 11.40 days respectively), higher than 
untreated mice (8.60 days). The prolonged survival 
time is probably due to curative action of the extracts. 
Interestingly methanol extract of F. africana was 
inactive with a mean survival time of 10.6 days. This 
implies as proposed by Dahanukar et al, (2000), that 
this plant extracts may possess other pharmacological 
benefits to the hosts, other than direct parasiticidal 
effects, such as acting as analgesics, antipyretics or as 
immune stimulators. On the contrary water extract of X. 
americana had a good activity with shorter mean 
survival time of 9.3 days. This indicates that the extracts 
act on the blood stages of the parasites, suggesting that 
the active compounds in these plant extract may have a 
short half-life. Some antimalarial drugs including 
artemisinine based derivatives are known to be fast 
acting, and to have a short half life (Muregi et al, 2007). 
In acute toxicity assay no deaths were observed for 
eight of the ten extracts at the highest concentration 
tested which was 5000 mg/kg body weight, indicating 
the safety of the plant extracts. Another pointer to the 
safety of most of the samples tested is that all the 
animals that received the extracts stayed alive for the 
entire period of the 4 day suppressive test. If the test 
mice die before day 5, then the cause of death may be 
attributed to the effect of the test drugs rather than the 
parasites  (Jutamaad et al, 1998) suggesting that the 
therapeutic index is too low. Moreover the doses of the 
extracts orally administered up to 5000mg/kg body 
weight were much higher than those taken as infusion 
by people. X. americana water extract displayed 
mortality though less than 50% of population. Since its 
antimalarial activity was encouraging and was not 
cytotoxic against Vero E99 cell lines the plant can still 
be used at safe doses as an antimalarial. Furthermore 
safe antimalarial compounds can still be isolated from 
the plant. 
The methanol extract of F. africana had good 
antimalarial activity with no signs of acute toxicity in 
mice. However it exhibited moderate cytotoxicity (CC50 
of 63.45 µg/ml) with selectivity index of 34.465 on Vero 
E99 cells, meaning its antiplasmodial activity was not 
due to cytotoxicity as described by Vonthron-Senecheau 
et al, (2003). For this reason, safe antimalarial 
compounds can be pursued from this plant (Kokwaro 
1993; Baraza et al, 2008). The findings here 
demonstrate the potential of this plant as a safe 
antimalarial. Most extracts were not cytotoxic on Vero E 
99 cell lines (CC50 values ≥100 µg/ml), suggesting the 
safety of the medicinal plants that have been used over 
many years.. 
5. Conclusion 
Antiplasmodial potential of the four selected medicinal 
plants used in Kenya has been demonstrated in this 
study. The observed high in vitro activity indicates their 
high potential and should therefore be pursued further 
for development of new antimalarial drugs. This study 
supports the use of P. lanceolata and X. americana as 
traditional antimalarials. Lack of cytotoxicity of most of 
the plant extracts  demonstrates the safety of these 
medicinal plants that have been used for a long time. 
Methanol extract of F. africana (aerial parts) though 
moderately cytotoxic can still be administered at safe 
doses. The fact that most of the plant extracts were not 
toxic to mice at 5000mg/kg body weight, validates their 
use in high doses as used by traditional medicine. Since 
X. americana water extract showed mortality of less 
than 50% of the population, it can still be used as 
antimalarial at safe lower doses in traditional medicine. 
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